Fritextsökning
Artiklar per år
Innehållstyper
-
Relax at the After Fair
Round off the first day of the fair by visiting the After Fair. You can reload with entertainment from talented artists such as Patrik Isaksson, The Gentlemen and Ellinor Asp and take the opportunity to mingle with old and new aquaintances.
-
New type of stem cell discovered
The earlier view of the scientific community was that melanocytes, the pigment cells, derive from the spinal cord during the early fetal period and then move over on to the skin.
-
Anything is measurable
At the seminar "Du är vad jag mäter - hjärnans kemi i ett provrör", Jonas Bergquist, professor of analytical chemistry and neurochemistry, will dig deep into the research of analyzing markers in body fluids.
-
BMAs: Run your own business
After graduation you must decide: be an employee or start your own business. This is not really the situation for BMAs today, but a collaborative project between Swedish public actors and some companies aims to change that and make entrepreneurs of BMAs.
-
Diagnostics for personalized medicine
Per Matsson from Phadia anticipates changes in the standards for health care. Accordiing to him, expensive new drugs will create a market for more extensive diagnostics.
-
Mingling do's and don'ts
Linkedin, Facebook, MSN and Gmail are all perfect tools for the urban businessman or woman to keep track of and stay up-to-date with contacts. "But in the end, networking is about meeting and talking to people face-to-face," says mingling expert Mia
-
A crash course in IP strategy
"Publish, publish, publish!" Sound familiar? So to meet the researcher's wishes, do you scribble a patent application with lipstick on a napkin and send it in? At the seminar Patent Strategies in the Biotech Company, you will have the chance to find out why this might not be the best idea.
-
Diagnostics to deal with new diseases
Maria Brytting at the Swedish Institute for Infectious Disease Control, SMI, will share her experiences from April 2009 when the new influenza A virus, H1N1, was first reported globally.
-
Young, bright and committed to labtech
, becoming the new CEO of Swedish Labtech.
-
Age essential when testing drugs
Anders Rane has been arguing that genes and age are both important factors in understanding how medicines affect individuals. Only last year, the EU established regulations stating that pharmaceuticals must be tested for children as well as for adults.
-
From planning stage to handshake
"Partnering is an effective tool to get in touch with the decision makers high up in an organization's administration," says Camilla Huse Bondeson at Conlega. And according to her, rigorous planning is the way to succeed.
-
Cate Poulsen, Qiagen
Why are you going to Scanlab and Biotech Forum?
-
Ny ELISA för diabetesforskare
Alpco lanserar två nya ELISA-kit för kvantifiering av plasmahalter av hormonet GLP-1.
-
With their hands on the legal levers
It is wonderful news for the Scandinavian scientific community. At the end of May it stood clear that Lund will host to the European Spallation Source.
-
The winner of the race
She learned how to work hard at an early age and her devotion has certainly paid off. Whether it is field running or running a company, the key to success is focus according to Yvonne Mårtensson.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Athera signs production partnership
The companys novel cardiovascular product will be manufactured in Germany.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
EU says yes to Roche drug
EU approves a first in class therapy for treatment of patients with moderate to severe form of rheumatoid arthritis.
-
Biotech goes white and bright
White biotech could become Denmark's next blossoming business area.
-
Swedish nanotech crosses the Atlantic
Genovis signs distribution agreement Finnzymes in US.
-
Parnevik firm in Swiss osteoporosis deal
The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.
BREAKING